


Supplemental Figures for:
Female representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies


Jonathan M Loree et al.

Supplementary Figure 1: Odds Ratio for female trial enrollment versus very high human development index country incidence or mortality

A



B




Caption: 1A) Odds Ratio (OR) for female trial enrollment compared to incidence by tumor type within very high human development index (HDI) countries and **1B)** OR for female trial enrollment compared to mortality in very high HDI countries.


Subcaption: Sex-specific cancers have been excluded. Female to male ratio (female:male) for trial enrollment and population incidence, OR and *P* value shown on the right.

Supplementary Figure 2: Odds Ratio for female trial enrollment versus global incidence or mortality

A




B



Caption: 2A) Odds Ratio (OR) for female trial enrollment compared to incidence globally by tumor type. **2B)** OR for female trial enrollment compared to mortality globally.

Subcaption: Sex-specific cancers have been excluded. Female to male ratio (female:male) for trial enrollment and population incidence, OR and *P* value shown on the right.

Supplementary Figure 3: Female and male distribution across US incidence, US mortality and 153 trials for 10 tumor types



Caption: Graphical representation of the ratio of females to males (female:male) within each of the 149 trials leading to FDA drug approvals during the period reviewed for the 10 most common non sex-specific tumor types in the US. The center of each circle specifies the tumor type represented. The inner ring denotes the female: male US incidence for that tumor type and the middle ring denotes the female:male US mortality for that tumor type. The outer ring of each circle represents female:male enrollment within each trial for that tumor.